Wells Fargo Maintains Overweight on Abbott Laboratories, Raises Price Target to $120
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice TargetHot
Wells Fargo analyst Larry Biegelsen maintains Abbott Laboratories (NYSE:ABT) with a Overweight and raises the price target from $119 to $120.
Wells Fargo analyst Larry Biegelsen maintains Abbott Laboratories (NYSE:ABT) with a Overweight and raises the price target from $119 to $120.